Dr Richard Torbett, Executive Director of commercial policy at the ABPI, said:
“Companies can’t charge the NHS what they want for a medicine, there is a strict value for money assessment by NICE and tough negotiations with the NHS on price.
“Additionally, the NHS has 100% certainty over the next five years on how much it will spend on branded medicines.
"This is the due to an agreement between pharmaceutical companies and the UK government."
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
To read more Press Release articles, click here.